Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590561 | 0.97 | — | — | |
| SCHEMBL7586949 | 0.83 | HSD17B1 (0.50) | APPESR1ESR2KDM4ENPC1 | |
| SCHEMBL15243106 | 0.83 | APP (0.44) | APPESR1ESR2 | |
| SCHEMBL498630 | 0.81 | DPP4 (0.53) | KDM4ENPC1GLAMAPTRAB9A | |
| SCHEMBL7590473 | 0.79 | RAB9A (0.48) | APPESR1ESR2KDM4ENPC1 | |
| SCHEMBL357574 | 0.78 | — | — | |
| SCHEMBL2592381 | 0.75 | DPP4 (0.53) | APPKDM4EMAPT | |
| SCHEMBL12293440 | 0.65 | — | — | |
| SCHEMBL2855363 | 0.65 | — | — | |
| SCHEMBL19089756 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379109-B1 | COMBINATION OF PHOTODYNAMIC THERAPY AND ANTI-VEGF AGENTS IN THE TREATMENT OF UNWANTED CHOROIDAL NEOVASCULATURE | BAUSCH HEALTH COMPANIES INC (CA) | 2020-10-07 | — | — | EP | disclosed |
| US-9226917-B2 | Photodynamic therapy for conditions of the eye | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-8968715-B2 | Drug delivery systems for photodynamic therapy | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2015-03-03 | — | — | US | disclosed |
| US-8852629-B2 | Drug delivery system for hydrophobic drugs | VALEANT PHARMACEUTICALS INTERNATIONAL, INC. (CA) | 2014-10-07 | — | — | US | disclosed |
| US-8710246-B2 | Substituted thiophene pentamers | BIOCHROMIX NEWCO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2012-06-21 | — | — | US | disclosed |
| EP-1357912-B9 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-06-13 | — | — | EP | disclosed |
| EP-1357912-B1 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QUADRA LOGIC TECH INC (CA) | 2012-04-25 | — | — | EP | disclosed |
| US-20120041356-A1 | PHOTODYNAMIC THERAPY FOR CONDITIONS OF THE EYE | QLT INC. (CA) | 2012-02-16 | — | — | US | disclosed |
| US-8106038-B2 | Method for reducing or preventing PDT related inflammation | QLT INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| WO-2002062386-A2 | PHOTODYNAMIC THERAPY OF OCCULT CHOROIDAL NEOVASCULARIZATION LINKED TO AGE-RELATED MACULAR DEGENERATION | QLT INC. (CA) | 2002-08-15 | — | — | WO | disclosed |
| US-20020061330-A1 | Supports for photosensitizer formulations | BRITISH COLUMBIA, THE UNIVERSITY OF (CA) | 2002-05-23 | — | — | US | disclosed |
| US-6355365-B1 | FOR USE IN ORGANIC ELECTRO LUMINESCENCE (EL) DEVICE; EFFICIENCY | JAPAN CHEMICAL INNOVATION INSTITUTE (JP) | 2002-03-12 | — | — | US | disclosed |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | QLT INC. (CA) | 2002-02-21 | — | — | US | disclosed |
| WO-2001085213-A2 | SUPPORTS FOR PHOTOSENSITIZER FORMULATIONS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| WO-2001085212-A2 | DRUG DELIVERY SYSTEMS FOR PHOTODYNAMIC THERAPY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2001-11-15 | — | — | WO | disclosed |
| EP-0477539-B1 | Tetracarboxylic acid dianhydrides | KANEGAFUCHI CHEMICAL IND (JP) | 1995-11-08 | — | — | EP | disclosed |
| US-5122617-A | Low thermal expansion polyimides | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-06-16 | — | — | US | disclosed |
| EP-0477539-A1 | Tetracarboxylic acid dianhydrides | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-04-01 | — | — | EP | disclosed |
| US-5045563-A | Terthienyl Compound | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY MINISTER OF NATIONAL DEFENCE OF HER MAJESTY'S CANADIAN GOVERNMENT (CA) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061330-A1 | Supports for photosensitizer formulations | PPOX, PPIF, SDHA | APP 3183/4885ESR1 3932/4885ESR2 3740/4885 |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | HSPE1, TTR, HTT | APP 87/4885ESR1 4607/4885ESR2 3648/4885 |
| US-20020022032-A1 | Immuno-adjuvant PDT treatment of metastatic tumors | CD74, ANXA11, ANXA1 | APP 2147/4885ESR1 2668/4885ESR2 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.